# PAVM earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/PAVM) · [Earnings tab](https://www.lopjlb.com/stock/PAVM?tab=earnings)

Updated: 2026-08-14T07:40:26

Quarters analyzed: 8

## Cross-quarter narrative

Across the earnings calls, PAVmed's narrative has shifted from focusing on funding risks and reimbursement challenges to highlighting progress in its subsidiaries, particularly Lucid and Veris. The company has made significant strides in restructuring its debt, securing financing for its subsidiaries, and advancing its products towards regulatory submissions and commercial launches. Despite ongoing challenges, including reimbursement uncertainty and regulatory risks, PAVmed's tone has become increasingly positive, reflecting its progress in executing its strategic plan and achieving key milestones.

## Latest CallCard · Q1

PAVmed completed cap table cleanup, relaunched device portfolio under new leadership, Lucid nears Medicare coverage, Veris advancing OSU rollout and implantable submission by year-end.

**Guidance:** vague — No explicit financial guidance provided; management discussed operational milestones but not quantitative targets.

**Tone:** mgmt 0.7 · Q&A pressure 0.3 · divergence 0.4

Management emphasizes completed restructuring, clean cap table, progress at Lucid and Veris, and active business development.

### Demand visibility

Lucid seeing early VA traction and pending commercial payer coverage; Veris OSU enrollment on track toward 1,000-patient target.

Lucid secured federal supply schedule with VA, first orders placed, pipeline expanding, positive coverage under one lab benefit manager to be public soon. Veris commercial phase at OSU expanding to new departments per rollout plan, EHR integration live, feedback excellent.

### Margins / costs

Q1 non-GAAP OpEx $5.9M, up $1.1M sequentially due to Veris R&D and recapitalization costs; future increases driven by implantable device development.

Non-GAAP operating expenses of $5.9M reflect $300K incremental Veris R&D and $800K in G&A for recapitalization financing and professional fees; management expects OpEx growth primarily from Veris implantable R&D supported by 2025 financings.

## Quarter one-liners

- **2026 Q1:** PAVmed completed cap table cleanup, relaunched device portfolio under new leadership, Lucid nears Medicare coverage, Veris advancing OSU rollout and implantable submission by year-end.
- **2025 Q4:** PAVmed completed restructuring, cleaned cap table, holds 31M Lucid shares; Lucid EsoGuard volume up 29% QoQ, VA contract won, Medicare pending; Veris OSU commercial launch underway with Epic integration, implantable FDA submission planned H2 2025; MedTech portfolio relaunch with new CBO, Duke endosc
- **2025 Q3:** PAVmed reports progress on debt restructuring, Lucid capital raise, Medicare endorsement for EsoGuard, and advances Veris partnership and implantable device development, while noting ongoing work on licensing and clinical support.
- **2025 Q1:** PAVmed highlights diversified subsidiary model with Lucid near Medicare decision, Veris restarting implantable monitor development toward FDA filing, and PMX seeking PortIO strategic partnership while exploring biopharma expansion.
- **2024 Q4:** PAVmed completed restructuring, deconsolidated Lucid, restructured debt, secured Veris financing; Lucid revenue $1.2M (+45% QoQ); Veris advancing implantable monitor toward FDA submission.
- **2024 Q3:** PAVmed completed strategic transformation via Lucid deconsolidation and debt restructuring to preserve NASDAQ listing; Veris pilot successful, seeking financing; PortIO term sheet signed; standalone breakeven.
- **2024 Q2:** PAVmed Q2 2024 update highlights record Lucid test volume, flat revenue, ongoing financing for Veris and PortIO, and a mid‑2025 target for the implantable monitor FDA submission.
- **2024 Q1:** PAVmed Q1 2024: Lucid EsoGuard revenue flat but volume +10% QoQ; Veris MOU with Ohio State for 100-patient pilot; PMX Incubator advancing PortIO fundraising; cash $25.5M ($37.1M pro forma); burn $11.7M/qtr; funding beyond 1yr depends on reimbursement ramp and subsidiary financing.

## Theme arcs

- **Funding and Reimbursement** (improving): PAVmed has secured financing for its subsidiaries and is making progress in reimbursement discussions
- **Regulatory Progress** (improving): Lucid and Veris are advancing their products towards regulatory submissions
- **Commercial Launches** (new): Veris is launching its product commercially with OSU, and Lucid is seeing early VA traction
- **Debt Restructuring** (resolved): PAVmed has completed its debt restructuring and cleaned up its cap table
- **Operational Efficiency** (stable): PAVmed's non-GAAP OpEx has remained relatively stable despite increases in R&D spending

## Fear persistence

- **Reimbursement Risk** [recurring]: Ongoing uncertainty around Medicare coverage for EsoGuard
- **Regulatory Risk** [recurring]: Risk of delays or rejections in regulatory submissions
- **Funding Risk** [resolved]: PAVmed has secured financing for its subsidiaries
- **Operational Risk** [new]: Reliance on clinical support services due to staff overload at partner centers
- **Partnership Risk** [new]: Success of Veris depends on expanding beyond OSU to other academic centers

## Guidance path

2024 Q1:vague → 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/PAVM`